AM Pharma
Business Development · Biotechnology
Overview
AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions.
Official records
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
A randomized phase 1b trial evaluating the pharmacodynamics of ilofotase alfa in adults with hypophosphatasia
View publication The post A randomized phase 1b trial evaluating the pharmacodynamics of ilofotase alfa in adults with hypophosphatasia appeared first on AM Pharma.
Read more
Report
AM-PHARMA COMPLETES ENROLLMENT IN PHASE 2 STUDY OF ILOFOTASE ALFA FOR PREVENTION OF CARDIAC SURGERY-ASSOCIATED RENAL DAMAGE
Utrecht, The Netherlands, October 2, 2025 - AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of cardiac surgery-associated renal dam
Read more
Report
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
Utrecht, The Netherlands, October 2, 2025 - AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of cardiac surgery-associated renal dam
Read more
Report
Improved VO₂max, muscle function and endurance in adult HPP "PAKO" mice treated with ilofotase alfa
View abstract The post Improved VO₂max, muscle function and endurance in adult HPP "PAKO" mice treated with ilofotase alfa appeared first on AM Pharma.
Read more
Report
AM-PHARMA INITIATES PHASE 2 TRIAL OF ILOFOTASE ALFA FOR CARDIAC SURGERY-ASSOCIATED RENAL DAMAGE
Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa's clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication
Read more
Report